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Peripheral blood monocytes are responsible for cd T cell
activation induced by zoledronic acid through accumulation
of IPP/DMAPP
Nitrogen-containing bisphosphonate drugs (N-BPs) are effec-
tive anti-resorptive agents commonly used for the treatment
of postmenopausal osteoporosis and tumour-induced osteo-
lysis. Intravenous administration of N-BPs is commonly
associated with a flu-like acute-phase reaction involving the
activation of Vc9Vd2 T cells (Kunzmann et al, 2000). As
Vc9Vd2 T cells have potent anti-tumoural properties, acti-
vation and expansion of Vc9Vd2 T cells by N-BPs offers a
promising strategy for cancer immunotherapy (Bonneville &
Scotet, 2006). N-BPs, like dietary alkylamines, activate
Vc9Vd2 T cells through inhibition of farnesyl diphosphate
(FPP) synthase (Gober et al, 2003; Thompson & Rogers,
2004; Hewitt et al, 2005; Thompson et al, 2006a), most likely
via an accumulation of the substrates of FPP synthase,
isopentenyl diphosphate (IPP) and its stereoisomer dimeth-
ylallyl diphosphate (DMAPP), which are agonists of the
Vc9Vd2 T cell receptor (TCR) (Tanaka et al, 1995). However,
the exact cell type in peripheral blood that accumulates IPP/
DMAPP after exposure to N-BP remains unknown. Mono-
cytes have previously been shown to be required for
activation of Vc9Vd2 T cells by the N-BP pamidronate
(Miyagawa et al, 2001), although the role of monocytes was
thought to be direct presentation of N-BP to the Vc9Vd2
TCR (Miyagawa et al, 2001). It has since become clear that
the activation of Vc9Vd2 T cells by N-BPs involves intracel-
lular N-BP uptake and IPP/DMAPP accumulation (Gober
et al, 2003; Thompson & Rogers, 2004). We hypothesized
that monocytes, due to their high endocytic activity, are the
peripheral blood cells that efficiently internalize N-BP and
accumulate IPP/DMAPP, and therefore are directly respon-
sible for triggering Vc9Vd2 T cell activation.
Materials and methods
Reagents
Zoledronic acid (ZOL) and CGP-58318 (an analogue of ZOL;
Legay et al, 2002) were provided by Novartis Pharma AG
(Basel, Switzerland). All other reagents were from Sigma
Chemical Company (Poole, Dorset, UK), unless otherwise
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Summary
Nitrogen-containing bisphosphonates indirectly activate Vc9Vd2 T cells
through inhibition of farnesyl pyrophosphate synthase and intracellular
accumulation of isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP), but the cells responsible for Vc9Vd2 T cell
activation through IPP/DMAPP accumulation are unknown. Treatment of
human peripheral blood mononuclear cells (PBMCs) with a
pharmacologically relevant concentration of zoledronic acid induced
accumulation of IPP/DMAPP selectively in monocytes, which correlated
with efficient drug uptake by these cells. Furthermore, zoledronic acid-pulsed
monocytes triggered activation of cd T cells in a cell contact-dependent
manner. These observations identify monocytes as the cell type directly
affected by bisphosphonates responsible for Vc9Vd2 T cell activation.
Keywords: bisphosphonates, alkylamines, monocytes, gamma delta T cells,
isopentenyl diphosphate.
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stated. Mevastatin (MEV) was converted from the lactone
form by dissolving 5 mg in 100 ll of ethanol and 100 ll 1 N
NaOH, adding 1 ml phosphate buffered saline (PBS), and
adjusting the pH to 8 using 1 N HCl. CGP-58318 was
conjugated through the primary amine group to Alexa Fluor
488 (AF488-BP) or Alexa Fluor 680 (AF680-BP) as previously
described for alendronate (Thompson et al, 2006b).
Cell culture and treatment
This study was approved by the North of Scotland Research
Ethics Committee. Informed consent was obtained for the
collection of peripheral blood from healthy volunteers in
accordance with the Declaration of Helsinki. Peripheral blood
mononuclear cells (PBMCs) were isolated using Lymphoprep
(Axis-Shield, Oslo, Norway) density gradient centrifugation
and cultured in a-minimal essential medium supplemented
with 100 U/ml penicillin, 100 lg/ml streptomycin, 2 mmol/l
glutamine, 10% fetal bovine serum, and 10 U/ml recombinant
human interleukin 2, except for detection of drug uptake
where PBMCs were isolated using PharmLyse (BD Biosciences,
Oxford, UK). Murine J774Æ2 macrophage-like cells were
cultured as previously described (Thompson et al, 2006b),
and plated at 5 · 105 cells/well in 6-well plates and allowed to
adhere overnight. The cells were then treated as indicated in
the figure legends for 24 h before harvesting.
Detection and quantification of IPP/DMAPP and ApppI
Human PBMCs (2 · 106 cells/ml in 75 cm2 flasks) or J774Æ2
macrophages (5 · 105 cells/well in 6-well plates) were treated
as indicated in the figure legends, and T cells or monocytes
were purified from human PBMCs by negative selection using
MACS beads (Miltenyi Biotech GmbH, Bergisch Gladbach,
Germany) according to manufacturer’s instructions. IPP/
DMAPP and ApppI were quantified by high performance
liquid chromatography negative ion electrospray ionization
mass spectrometry (HPLC-ESI-MS) in acetonitrile extracts, as
previously described (Mo¨nkko¨nen et al, 2006), and results
were expressed per milligram protein, determined by Bradford
assay.
Detection of drug uptake
Human PBMCs (1 · 106 cells/well in 24-well plates) were
treated as indicated in the legend of Fig 1, washed twice in ice-
cold PBS, and stained with anti-CD14 (Miltenyi Biotech) or
anti-CD3 antibodies (Beckman Coulter Immunotech, Palo
Alto, CA, USA). Formaldehyde-fixed cells were analysed on an
LSRII (BDBiosciences) flow cytometer using facsdiva software
(BD Biosciences), or cytospun onto slides and counterstained
with SYTOX Orange (Invitrogen, Paisley, UK) prior to analysis
on a Zeiss LSM510 META system (Carl Zeiss Ltd, Welwyn
Garden City, UK) using a 63· objective lens, and aim software
(Carl Zeiss Ltd) for image acquisition and analysis.
Co-culture of ZOL-treated monocytes with cd T cells
Monocytes were isolated from human PBMCs using anti-CD14
magnetic bead separation (Miltenyi Biotec GmbH) according to
the manufacturer’s instructions. Purity of the monocyte fraction
was ‡93%, as assessed by CD14-labelling and flow cytometric
analysis. Isolatedmonocytes were plated out at 5 · 105 cells/well
in 24-well plates, pulse-treated with 1 lmol/l ZOL or vehicle for
2 h, then washed with PBS. Vehicle- or ZOL-treated monocytes
(1 · 105 cells/well) were then co-cultured with the monocyte-
depleted PBMCs (5 · 105 cells/well) or with cd T cells
(1 · 104 cells/well) isolated from the monocyte-depleted frac-
tion using a negative cd T cell isolation kit (Miltenyi Biotec
GmbH), in a final volume of 500 ll medium in 24-well plates. To
assess the role of cell–cell contact, transwell inserts (pore-size
0Æ4 lm) were used to separate monocyte-depleted PBMCs or cd
T cells from monocytes.
Detection of interferon-c release
After 72 h, conditioned medium was collected and the
concentration of interferon (IFN)-c was determined using an
IFN-c Quantikine enzyme-linked immunosorbent assay kit
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
Detection of cd T cell proliferation
After 7 d, the percentage of Vd2-TCR+ T cells in the PBMC
co-cultures was determined by immunostaining with anti-CD3
and anti-Vd2-TCR antibodies and flow cytometric analysis, as
previously described (Thompson et al, 2006a).
Results and discussion
ZOL and sec-butylamine induce IPP/DMAPP
accumulation in J774Æ2 macrophages and this is prevented
by mevastatin
Recent studies have suggested that accumulation of IPP/
DMAPP triggers Vc9Vd2 T cell activation by N-BPs as well as
alkylamines (Gober et al, 2003; Thompson & Rogers, 2004;
Hewitt et al, 2005; Thompson et al, 2006a). However, the IPP/
DMAPP accumulation in response to pharmacological inhibi-
tion of FPP synthase is not well characterized. We used
quantitative HPLC-ESI-MS to assess intracellular IPP/DMAPP
levels in response to ZOL treatment in J774Æ2macrophages. Low
concentrations of ZOL (‡0Æ5 lmol/l) were sufficient to cause
detectable accumulation of IPP/DMAPP (Fig S1A). In addition,
the alkylamine sec-butylamine (SBA) also induced IPP/DMAPP
accumulation at concentrations ‡5 mmol/l (Fig S1A). The
relatively high concentration of SBA required to induce IPP/
DMAPP accumulation correlated with the far lower potency of
alkylamines for inhibiting FPP synthase than ZOL (Thompson
et al, 2006a). Simultaneous treatment with MEV almost com-
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Fig 1. ZOL induces IPP/DMAPP accumulation selectively in monocytes and this is associated with high levels of intracellular drug uptake. (A) Human
PBMCswere pulse-treated with 1 lmol/l ZOL for 2 h, washed and further cultured for 22 h in drug-freemedium. Cells were purified intomonocyte and
non-monocyte fractions using magnetic bead separation and IPP/DMAPP was detected in acetonitrile cell extracts by HPLC-ESI-MS. Data shown are
representative of two experiments from independent donors. Chromatograms were drawn on the same scale. No IPP/DMAPP was detected in extracts
from untreated cells. (B–D) Human PBMCs were treated with 20 lmol/l AF680-BP for 24 h, washed, and stained with either anti-CD3-fluorescein
isothiocyanate (FITC) or anti-CD14-FITC. Fixed cells were then analysed on an LSRII flow cytometer. Representative fluorescence scatter plots are shown
of control cells and cells treated with AF680-BP, labelled with anti-CD14-FITC (B) or anti-CD3-FITC (C). CD3-stained cells were gated for the
lymphocyte population based on forward versus side scatter profile. (D) Quantification of results shown in panels B and C using facsdiva software.
Results are corrected for background fluorescence, and data are expressed asmean ± standard error of themean relative fluorescence units (RFU) of nine
independent donors from five experiments. (E–F) Human PBMCs were treated with (E) either 50 lmol/l AF488-BP (green) or 250 lg/ml FITC-dextran
(green), or (F) 50 lmol/l AF488-BP (green) and 250 lg/ml TRITC-dextran (red), for 24 h. Cells were washed and stained with anti-CD14-allophyc-
ocyanin antibody (blue). Cell nuclei were visualised in (E) by counter-staining with SYTOX Orange (red). Formaldehyde-fixed and cytospun cells were
analysed on a Zeiss LSM510 META system. White bars indicate 10 lm. Images show representative results from at least two independent donors.
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pletely prevented the ZOL- or SBA-induced IPP/DMAPP
accumulation (Fig S1A). These findings provide further
evidence for the notion that statins, through inhibiting HMG-
CoA reductase upstream of FPP synthase, prevent
N-BP- and alkylamine-induced Vc9Vd2 T cell activation by
preventing the accumulation of IPP/DMAPP resulting fromFPP
synthase inhibition (Gober et al, 2003; Thompson & Rogers,
2004; Hewitt et al, 2005; Thompson et al, 2006a), and further
confirm the mechanism of Vc9Vd2 T cell activation and
proliferation by FPP synthase inhibitors. The accumulation of
IPP/DMAPP in J774Æ2 cells in response to both ZOL and SBA
was associated with a concurrent accumulation of the recently
identified novel IPPmetabolite ApppI (Mo¨nkko¨nen et al, 2006),
and this was also blocked by MEV (Fig S1B). Whether the
metabolism of IPP into ApppI affects the activation of Vc9Vd2 T
cells by N-BPs or alkylamines is presently unknown.
Monocytes accumulate IPP/DMAPP in response
to ZOL in human PBMC cultures
To investigate which cell type in peripheral blood is responsible
for the IPP/DMAPP accumulation and resulting Vc9Vd2 T cell
activation byN-BPs, we assessed intracellular IPP/DMAPP levels
in human PBMC cultures in response to ZOL treatment. IPP/
DMAPP could not be detected in untreated cells, but when
human PBMCs were pulsed for 2 h with 10 lmol/l ZOL, IPP/
DMAPP was clearly detectable in the non-T cell fraction,
whereas T cells showed only minor levels of IPP/DMAPP (Fig
S2). The MS/MS spectrum from the peak in the non-T cell
fraction was identical to the MS/MS spectrum of synthetic IPP
(not shown). When human PBMCs were pulsed with 1 lmol/l
ZOL for 2 h (to mimic the estimated circulating concentration
and exposure of peripheral blood cells following a standard dose
of ZOL in vivo; Chen et al, 2002), ZOL-induced IPP/DMAPP
accumulation was clearly detectable in monocytes purified by
magnetic bead separation, but hardly detectable in the non-
monocyte fraction (Fig 1A). Isolation of monocytes based on
cell adherence yielded similar results (not shown).
Peripheral blood monocytes efficiently internalize N-BP
We have shown recently that fluid-phase endocytosis is the
major route by which N-BPs are internalized in J774Æ2
macrophages and osteoclasts (Thompson et al, 2006b). Since
peripheral blood monocytes are highly endocytic, we investi-
gated whether the selective accumulation of IPP/DMAPP in
this cell type correlated with relatively high levels of drug
uptake. Indeed, in cultures of PBMCs, only CD14+ monocytes
internalized large amounts of fluorescently labelled N-BP,
while little or no uptake by other cell types, including CD3+
lymphocytes, could be detected at the concentrations and
treatment duration used (Fig 1B-D). Similarly, only mono-
cytes internalized large amounts of dextran (Fig 1E), a marker
of fluid-phase endocytosis, and confocal microscopy demon-
strated intracellular co-localization of fluorescently labelled
N-BP with dextran (Fig 1F). This suggests that N-BP uptake by
peripheral blood monocytes, similar to that by J774Æ2 macro-
phages and osteoclasts (Thompson et al, 2006b), predomi-
nantly occurs via fluid-phase endocytosis. Together, these
findings indicate that, following an intravenous infusion of
ZOL, only highly endocytic monocytes in peripheral blood are
likely to internalize sufficient ZOL to cause a significant
accumulation of IPP/DMAPP.
ZOL-pretreated monocytes activate Vc9Vd2 T cells in
human PBMC cultures, and this is dependent
on cell–cell contact
Having shown that monocytes accumulate detectable levels of
IPP/DMAPP following treatment with a clinically relevant
pulse of ZOL (1 lmol/l for 2 h), we investigated whether
purified peripheral blood monocytes pretreated with the same
concentration and duration of ZOL activated Vc9Vd2 T cells
in co-cultures with untreated (monocyte-depleted) PBMCs.
ZOL-treated monocytes induced a 2Æ5 ± 1Æ2-fold (n = 3)
increase in IFN-c release when co-cultured with monocyte-
depleted PBMCs, as compared to co-culture of monocyte-
depleted PBMCs with vehicle-treated monocytes (Fig 2A),
although this did not reach statistical significance. The increase
in IFN-c correlated with a 2Æ1 ± 0Æ5-fold (n = 3) increase
(P < 0Æ05) in Vd2+ T cell number after a 7 d culture (Fig 2B),
and an increase in cell clustering (not shown) in co-cultures
with ZOL-treated monocytes as compared to co-cultures with
vehicle treated-monocytes. Both IFN-c release and Vd2+ T cell
proliferation were prevented when the monocyte-depleted
PBMCs were separated from monocytes using transwell
inserts, indicating that cell–cell contact is required for the
activation of Vc9Vd2 T cells by ZOL-treated monocytes.
ZOL-pretreated monocytes activate purified cd T cells
Finally, we investigated whether ZOL-pretreated monocytes
activated Vc9Vd2 T cells in enriched cd T cell cultures. After
72 h, IFN-c release was significantly increased in co-cultures
of cd T cells with ZOL-treated monocytes, compared to
co-cultures with vehicle-treated monocytes (P < 0Æ05; Fig 2C).
As observed in the co-cultures of monocytes with monocyte-
depleted PBMCs, the increase in IFN-c release was abrogated
when cd T cells were separated from monocytes using
transwell inserts (Fig 2C). This strongly suggests that ZOL-
treated monocytes can directly activate cd T cells via a cell
contact-dependent mechanism.
Conclusions
This study demonstrated that ZOL induced IPP/DMAPP
accumulation selectively in monocytes following treatment
with a clinically-relevant dose and duration of ZOL, most
probably a result of efficient intracellular drug uptake by this
highly endocytic cell type. Furthermore, peripheral blood
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monocytes pretreated with ZOL induced activation and
proliferation of Vc9Vd2 T cells, both in mixed PBMC cultures,
and in co-cultures with enriched cd T cells. These findings
provide a novel explanation for why monocytes are essential
for Vc9Vd2 T cell activation by N-BPs, and suggest that
monocytes, following exposure to ZOL, can directly activate
Vc9Vd2 T cells in a cell contact-dependent manner.
Acknowledgements
The authors would like to thank Mrs. Denise Tosh and Mrs.
Pat Crombie for technical assistance, Mrs. Linda Duncan for
assistance with flow cytometry, and Dr. K. Jaeggi for synthesis
of CGP-58318. This study was supported by research funding
from Novartis Pharma AG (M.J.R. and K.T.), and grants from
Cancer Research UK, grant number C13325 (M.J.R and
A.J.R.), and The Academy of Finland (H.M. and J.M.).
Author contributions
A.J.R., M.J.R., J.M., and K.T. designed research; A.J.R., M.J.,
H.M., and K.T. performed research, collected data, and
analysed and interpreted data; A.J.R. and K.T. wrote the
manuscript; M.J., H.M., M.J.R. and J.M. contributed to writing
the manuscript.
References
Bonneville, M. & Scotet, E. (2006) Human Vc9Vd2 T cells: promising
new leads for immunotherapy of infections and tumors. Current
Opinion in Immunology, 18, 539–546.
Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S.,
LoRusso, P., Ma, P., Ravera, C., Deckert, F., Schran, H., Seaman, J. &
Skerjanec, A. (2002) Pharmacokinetics and pharmacodynamics of
zoledronic acid in cancer patients with bone metastases. Journal of
Clinical Pharmacology, 42, 1228–1236.
Gober, H.J., Kistowska, M., Angman, L., Jeno, P., Mori, L. & De
Libero, G. (2003) Human T cell receptor gammadelta cells recognize
endogenous mevalonate metabolites in tumor cells. Journal of
Experimental Medicine, 197, 163–168.
Hewitt, R.E., Lissina, A., Green, A.E., Slay, E.S., Price, D.A. & Sewell,
A.K. (2005) The bisphosphonate acute phase response: rapid and
copious production of proinflammatory cytokines by peripheral
blood cd T cells in response to aminobisphosphonates is inhibited
by statins. Clinical and Experimental Immunology, 139, 101–111.
Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H.P. &
Wilhelm, M. (2000) Stimulation of gammadelta T cells by amin-
obisphosphonates and induction of antiplasma cell activity in
multiple myeloma. Blood, 96, 384–392.
Legay, F., Gauron, S., Deckert, F., Gosset, G., Pfaar, U., Ravera, C.,
Wiegand, H. & Schran, H. (2002) Development and validation of a
highly sensitive RIA for zoledronic acid, a new potent heterocyclic
bisphosphonate, in human serum, plasma and urine. Journal of
Pharmaceutical and Biomedical Analysis, 30, 897–911.
Miyagawa, F., Tanaka, Y., Yamashita, S. & Minato, N. (2001) Essential
requirement of antigen presentation by monocyte lineage cells for
the activation of primary human gamma delta T cells by amino-
bisphosphonate antigen. Journal of Immunology, 166, 5508–5514.
Mo¨nkko¨nen, H., Auriola, S., Lehenkari, P., Kellinsalmi, M., Hassinen,
I.E., Vepsa¨la¨inen, J. & Mo¨nkko¨nen, J.A. (2006) A new endogenous
(A)
(B)
(C)
Fig 2. Activation of Vc9Vd2 T cells by ZOL-treated monocytes.
Monocytes were purified from human PBMCs by CD14 magnetic bead
isolation and pulsed with vehicle or 1 lmol/l ZOL for 2 h. Vehicle-
or ZOL-treated monocytes were then co-cultured with monocyte-
depleted PBMCs (A, B) or cd T cells obtained from monocyte-depleted
PBMCs using a cd T cell magnetic bead isolation kit (C). Transwell
inserts were used to separate the monocytes from the PBMCs or the
enriched cd T cells. After 72 h, the concentration of IFN-c in the cell
culture medium was determined by enzyme-linked immunosorbent
assay (A, C). To determine proliferative responses, the proportion of
Vd2+ T cells in the CD3+ population was determined by immunola-
belling and flow cytometric analysis after 7 d of culture and expressed
relative to control (B). Data is shown as mean ± standard deviation of
3 independent donors. *P < 0Æ05 as compared to vehicle-treated
control.
Short Report
ª 2008 The Authors
Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 144, 245–250 249
ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide
translocase (ANT) and is responsible for the apoptosis induced by
nitrogen-containing bisphosphonates. British Journal of Pharmacol-
ogy, 147, 437–445.
Tanaka, Y., Morita, C.T., Tanaka, Y., Nieves, E., Brenner, M.B. &
Bloom, B.R. (1995) Natural and synthetic non-peptide antigens
recognized by human gamma delta T cells. Nature, 375, 155–158.
Thompson, K. & Rogers, M.J. (2004) Statins prevent bisphosphonate-
induced gamma delta-T-cell proliferation and activation in vitro.
Journal of Bone and Mineral Research, 19, 278–288.
Thompson, K., Rojas-Navea, J. & Rogers, M.J. (2006a) Alkylamines
cause Vc9Vd2 T-cell activation and proliferation by inhibiting the
mevalonate pathway. Blood, 107, 651–654.
Thompson, K., Rogers, M.J., Coxon, F.P. & Crockett, J.C. (2006b)
Cytosolic entry of bisphosphonate drugs requires acidification of
vesicles after fluid-phase endocytosis. Molecular Pharmacology, 69,
1624–1632.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Fig S1. Mevastatin prevents both ZOL- and SBA-induced
IPP/DMAPP and ApppI accumulation in J774Æ2 macrophages.
Fig S2. ZOL-induced IPP/DMAPP accumulation occurs
predominantly in non-T cells in human PBMC cultures.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the
article.
Short Report
ª 2008 The Authors
250 Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 144, 245–250
